As shares tank, Or­chard once again re­struc­tures, shed­ding gene ther­a­py pro­grams and a large part of the staff

Al­most ex­act­ly 2 years ago, Or­chard Ther­a­peu­tics ex­ecs re­or­ga­nized the pipeline, shed staff and cir­cled their wag­ons around what they con­sid­ered the most vi­tal part of its R&D ef­fort. To­day, they’re go­ing back in to cut again, tak­ing out once key pro­grams while des­ig­nat­ing a new line­up as es­sen­tial to its fu­ture.

Or­chard, a UK/US hy­brid gene ther­a­py com­pa­ny, is tak­ing the ax to ther­a­pies for rare pri­ma­ry im­mune de­fi­cien­cies. These in­clude: OTL-103 for Wiskott-Aldrich syn­drome, OTL-102 for X-linked chron­ic gran­u­lo­ma­tous dis­ease and Strimvelis, a gam­maretro­vi­ral vec­tor-based gene ther­a­py ap­proved in Eu­rope for adeno­sine deam­i­nase se­vere com­bined im­mun­od­e­fi­cien­cy (ADA-SCID).

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN